Disfunzioni sessuali post-SSRI

Australian Journal of General Practice, Volume 50, Issue 12, December 2021 Antidepressant prescribing in general practice: A call to action Katharine A Wallis     Maria Donald     Joanna Moncrieff    doi: 10.31128/AJGP-02-21-5828 The  Mental health: Productivity Commission inquiry report  (2020) recommended as a ‘priority reform’ that we ‘[a]ddress adverse outcomes from prescribing practices of mental health medication’. 1  The report states that ‘while antipsychotic prescribing in aged care facilities is one element of this … arguably a greater concern, given its frequency, is antidepressant prescribing’. 1  The report recommends that general practitioner (GP) ‘mental health training and professional development’ be improved to increase ‘adherence to evidence-based clinical practices (including the clinical appropriateness of GP’s [sic] prescribing practices for mental health medication, management of medication side effects and de-prescribing)’. 1  This article discusses antidepressa

Expert Opin Drug Saf .  2021 Nov 18. PMID:  34791958   DOI:  10.1080/14740338.2022.2007883 Persistent sexual dysfunction after SSRI withdrawal: a scoping review and presentation of 86 cases from the Netherlands Katherine Chinchilla Alfaro   1 ,  Florence van Hunsel   1 ,  Corine Ekhart   1 1 Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands. Abstract Background:  Sexual dysfunction is highly prevalent worldwide. A specific form is persistent sexual dysfunction after SSRI withdrawal. We conducted a systematic literature review in order to characterize factors related to post SSRI sexual dysfunction (PSSD) and analyzed spontaneous reports of persistent sexual dysfunction reported to the Netherlands Pharmacovigilance Centre Lareb. Research design and methods:  A systematic literature review was conducted following the PRISMA-ScR guidelines. In addition, reports of PSSD submitted to the Netherlands Pharmacovigilance Centre Lareb between 1992 and 2021 were an

Abstract presented in the context of: The International Society of Pharmacovigilance (ISoP) 20th ISoP Annual Meeting “Integrated pharmacovigilance for safer patients” 8–10 November 2021 Muscat, Oman https://link.springer.com/article/10.1007/s40264-021-01129-0 P060 Persistent Sexual Dysfunction in SSRI Users: Scoping Review and Presentation of 93 Cases from The Netherlands K. Chinchilla 1 , F. van Hunsel 1 ,  C. Ekhart   1 1 Netherlands Pharmacovigilance Centre Lareb, Signal Detection, ‘s-Hertogenbosch, The Netherlands Background/Introduction:  SSRIs are potent disruptors of sexual function. These effects can persist after the discontinuation of the SSRI, leading to Post SSRI Persistent Sexual Dysfunction (PSSD). This refers to a hypodynamic sexual state that can persist for decades carrying a high impact on the patient’s life (1, 2). Objective/Aim:  To map the characteristic factors related to PSSD through a literature review, and present the cases of PSSD received by the Netherlands p

'Qualcosa di così sacro mi è stato portato via' Gli antidepressivi aiutano milioni di persone. Ma per alcuni portano un devastante effetto collaterale sessuale Moira Wyton, 2 Novembre 2021, TheTyee.ca Emily prendeva l'antidepressivo Citalopram da quando aveva 17 anni, prima ancora che il sesso entrasse nell'equazione per lei. Dopo cinque anni, ne aveva avuto abbastanza. Come circa il 65 per cento delle persone che prendono inibitori selettivi della ricaptazione della serotonina, o SSRI - alcuni ricercatori credono che il numero è ancora più alto - Emily ha sperimentato l'effetto collaterale di bassa libido. Ma per un po' sembrava che ne valesse la pena per il sollievo dalla sua depressione moderata. Prendeva la piccola pillola rosata ogni giorno, e la vita sembrava migliorare un po'. Poi, a 23 anni nel 2019, Emily disse al suo medico che la disfunzione sessuale la stava privando della connessione e della fiducia nella sua vita. La sua depressione non era mi